Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Book serves to highlight the mechanisms related to the low intestinal drug absorption, the strategies to overcome the obstacles or intestinal drug absorption, and in situ, in vitro, and in silico methodologies to predict to intestinal drug absorption. This Book presents a series of drug absorption studies and related technologies that predict intestinal permeation of drugs that govern the pharmacokinetic features of therapeutic drugs. It also contains the mechanistic understanding regarding the first-pass metabolism and intestinal efflux that modulate the pharmacokinetics of drug and suggest the formulation strategies to enhance the bioavailability of investigated drugs.

Medicine --- Pharmaceutical industries --- rebamipide --- nanocrystals --- oral mucositis --- hydrogel --- endocytosis --- enoxaparin --- lipid–polymer hybrid nanoparticles --- oral --- intestinal absorption --- naftidrofuryl oxalate --- solubility --- permeability --- dissolution profiles --- pharmaceutical availability --- BCS drug classification --- non-sink condition --- solubility–permeability interplay --- unstirred water layer --- poorly soluble drugs --- solubilizer additive --- phenylketonuria --- l-phenylalanine ammonia-lyase --- enzyme --- kinetics --- catabolism disorder --- biomedical drug --- P-glycoprotein --- breast cancer resistance protein --- LY335979 --- WK-X-34 --- in vivo–in vitro correlation --- lipolysis-permeation --- lipid-based drug delivery system --- PermeaPad --- cinnarizine --- lipolysis --- amorphous solid dispersion --- candesartan Cilexetil --- PVPK30 --- pH-modulation --- spray drying --- bioavailability --- nasal administration --- spray-drying --- chitosan --- microsphere --- meloxicam --- silymarin --- D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) --- liver distribution --- acetaminophen-induced hepatotoxicity --- extra virgin olive oil --- secoiridoids --- metabolism --- phenolic compounds --- intestinal permeability --- drug-phytochemical interaction --- hepatic metabolism --- mixed inhibition --- quercetin --- repaglinide --- rebamipide --- nanocrystals --- oral mucositis --- hydrogel --- endocytosis --- enoxaparin --- lipid–polymer hybrid nanoparticles --- oral --- intestinal absorption --- naftidrofuryl oxalate --- solubility --- permeability --- dissolution profiles --- pharmaceutical availability --- BCS drug classification --- non-sink condition --- solubility–permeability interplay --- unstirred water layer --- poorly soluble drugs --- solubilizer additive --- phenylketonuria --- l-phenylalanine ammonia-lyase --- enzyme --- kinetics --- catabolism disorder --- biomedical drug --- P-glycoprotein --- breast cancer resistance protein --- LY335979 --- WK-X-34 --- in vivo–in vitro correlation --- lipolysis-permeation --- lipid-based drug delivery system --- PermeaPad --- cinnarizine --- lipolysis --- amorphous solid dispersion --- candesartan Cilexetil --- PVPK30 --- pH-modulation --- spray drying --- bioavailability --- nasal administration --- spray-drying --- chitosan --- microsphere --- meloxicam --- silymarin --- D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) --- liver distribution --- acetaminophen-induced hepatotoxicity --- extra virgin olive oil --- secoiridoids --- metabolism --- phenolic compounds --- intestinal permeability --- drug-phytochemical interaction --- hepatic metabolism --- mixed inhibition --- quercetin --- repaglinide